Newsroom
Sorted by: Latest
-
Tyler Technologies to Participate in March Investor Conferences
PLANO, Texas--(BUSINESS WIRE)--Tyler Technologies will participate in four investor conferences in March 2026....
-
Miami Freedom Park Selects Evolv Technology for All Guest Ingress Screening at New World-Class Stadium
WALTHAM, Mass.--(BUSINESS WIRE)--Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced that Evolv Express® has been selected for use stadium-wide at Inter Miami CF's new home located at Miami Freedom Park. Evolv Express Gen2 systems will be installed at the new 25,000-seat Florida stadium, which is slated to open on April 4, 2026. Evolv Express was designed to allow people to mo...
-
Virewirx Awarded $1.9M Small Business Innovation Research (SBIR) Contract from Office of the Under Secretary of War (OUSW)
SAN DIEGO--(BUSINESS WIRE)--Virewirx has been awarded a Phase II $1.9 million Small Business Innovation Research (SBIR) OUSW (R&E) FutureG contract from the Office of the Under Secretary of War (OUSW) to develop an advanced 5G system designed to perform reliably in challenging Radio Frequency (RF) environments. This breakthrough technology will enable mission-critical communications in previously impossible environments, ensuring warfighters maintain connectivity for coordination, safety, a...
-
Terreno Realty Corporation Announces Leases in Redondo Beach, CA
BELLEVUE, Wash.--(BUSINESS WIRE)--Terreno Realty Corporation Announces Leases in Redondo Beach, CA...
-
Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,659,565 shares of common stock, issued by the Company on January 27, 2025 (the “January 2025 Warrants”), February 20, 2025 (the “February 2025 Warrants”) and November 12, 2025 (the “November 2025 Wa...
-
McLane Company Unveils New McLane Fresh Products at Convenience Retailing University 2026
TEMPLE, Texas--(BUSINESS WIRE)--McLane Company unveils new McLane Fresh products at Convenience Retailing University 2026....
-
Northwell Health’s Gun Violence Prevention Forum: Spotlighting progress
NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Last year, the United States saw some of the lowest levels of gun violence on record, but there is more work to be done. As part of Northwell Health’s Raise Health series – which convenes bold thinkers twice a year to spark dialogue and drive action on today’s most pressing health care challenges – the spring 2026 Gun Violence Prevention Forum will bring together leaders from industry, health care, science and the community to highlight progress and acceler...
-
Workiva to Present at Upcoming Investor Conferences
NEW YORK--(BUSINESS WIRE)--Workiva Inc. (NYSE:WK), a leading, AI-powered platform for trust, transparency, and accountability, today announced its participation at the following events: Raymond James 47th Annual Institutional Investors Conference: Barbara Larson, Chief Financial Officer, and Mike Rost, Chief Strategy Officer, will present on March 2, 2026 at 9:15 a.m. Eastern Time. Morgan Stanley Technology, Media & Telecom Conference: Julie Iskow, President and Chief Executive Officer, wil...
-
Elevance Health Foundation Commits $2.3 Million to New Food as Medicine Programs Across the Country
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health Foundation has awarded 22 new grants totaling more than $2.3 million to support food as medicine programs across the country. These grants will help nonprofit organizations improve access to nutritious food and advance clinical outcomes for individuals and families experiencing food and nutrition insecurity, particularly those living with diet-related chronic conditions. This latest round of funding is part of the Foundation’s five-year, $150 milli...
-
Organon與Sebela Pharmaceuticals達成MIUDELLA®無荷爾蒙子宮內避孕器授權協議
紐澤西州澤西市--(BUSINESS WIRE)--(美國商業資訊)-- Organon (NYSE: OGN)是一家全球性醫療保健公司,其使命是提供有影響力的藥物和解決方案,以改善人們的日常健康。公司今日宣布已與Sebela Pharmaceuticals達成協議,獲得其無荷爾蒙銅質子宮內避孕器(IUD)避孕藥具MIUDELLA的全球獨家授權。本次交易的生效須經《哈特-史考特-羅迪諾反托拉斯改進法》審核,並獲得美國食品藥物管理局(FDA)對MIUDELLA替代供應鏈主體的核准,以及滿足若干其他條件。 MIUDELLA是近40年來美國獲准的首款無荷爾蒙銅質IUD,與Organon的商業化能力形成互補,將進一步推動Organon打造滿足女性多樣化生殖健康需求的產品組合的承諾。MIUDELLA於2025年2月24日獲FDA核准,用於育齡女性避孕,有效期最長可達三年,目前尚未上市銷售。MIUDELLA為尋求長效、可逆、無荷爾蒙避孕方式的女性提供了額外選擇。MIUDELLA採用獨特的柔性支架和全預裝置入器,置入管直徑僅3.7公釐,細小且呈錐形。1 根據協議條款,Organon將在交易完成時支付...